Geron Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Harout Semerjian
- Full Time Employees
- 258
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 919 East Hillsdale Boulevard Foster City CA United States of America 94404
- IPO Date
- Jul 31, 1996
- CIK
- 0000886744
- Website
- geron.com
- Similar Companies
- Business
- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company headquartered in Foster City, California and founded in 1990, develops and commercializes telomerase inhibitor therapeutics targeting hematologic malignancies. The company markets RYTELO (imetelstat), a first-in-class telomerase inhibitor indicated for adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units per eight weeks; it explores the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies, including ongoing Phase 3 clinical trials of imetelstat in relapsed/refractory myelofibrosis (IMproveMF trial, NCT04576156) and previously transfusion-dependent anemia in myelodysplastic syndromes (IMerge trial, NCT02598661). Geron operates primarily in the United States with a focus on oncology therapeutics for blood cancers. In November 2024, Geron secured up to $375 million in non-dilutive funding through synthetic royalty financing agreements with Royalty Pharma and Pharmakon Advisors, including an initial $125 million upfront payment for a royalty interest on U.S. net sales of RYTELO to support commercial launch, pipeline advancement, and general corporate purposes. The company reported fourth quarter and full-year 2024 financial results highlighting RYTELO commercialization progress, robust pipeline execution, and increased research and development investments into 2025 for ongoing clinical trials. Geron continues to prioritize global expansion of RYTELO access and telomerase-based therapies without noted acquisitions, partnerships beyond financing, or structural reorganizations in the past two years.
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Geron: Time To Reconsider This Oversold Biotech
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Plans to Present at Upcoming Investor Conferences
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)